Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIO-RT: IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer
NCT07166406Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Feb 2026
- Primary completion
- Mar 2029
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 5 years. Started Feb 2026; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07166406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166406.